Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)
December 23, 2009 updated by: Universitair Ziekenhuis Brussel
Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program
To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
130
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jette
-
Brussels, Jette, Belgium, 1090
- Centre for Reproductive Medicine, UZ Brussel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 36 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- FSH<12,
- normal sperm,less than 36y,
- single blastocyst transfer
Exclusion Criteria:
- endometriosis stage 3&4,
- pco
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Urinary-HCG group
These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
|
ovulation triggering
|
|
Experimental: Recombinant HCG group
These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
|
ovulation triggering
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
blastulation rate
Time Frame: on day-5
|
on day-5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
pregnancy rates, VEGF levels, OHSS rate
Time Frame: 14 days after oocyte pick up
|
14 days after oocyte pick up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Paul Devroey, Professor, Professor or OB-GYN
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Anticipated)
December 1, 2007
Study Completion (Anticipated)
September 1, 2010
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (Estimate)
August 7, 2009
Study Record Updates
Last Update Posted (Estimate)
December 24, 2009
Last Update Submitted That Met QC Criteria
December 23, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rec-HCG 002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.